Q1 Earnings Forecast for Sanofi Issued By Leerink Partnrs

Sanofi (NASDAQ:SNY) – Research analysts at Leerink Partnrs lifted their Q1 2025 EPS estimates for shares of Sanofi in a research note issued on Thursday, January 30th. Leerink Partnrs analyst D. Risinger now expects that the company will post earnings of $0.85 per share for the quarter, up from their prior estimate of $0.75. The consensus estimate for Sanofi’s current full-year earnings is $4.34 per share. Leerink Partnrs also issued estimates for Sanofi’s Q2 2025 earnings at $0.92 EPS, Q4 2025 earnings at $0.92 EPS and FY2029 earnings at $5.94 EPS.

SNY has been the subject of several other research reports. Deutsche Bank Aktiengesellschaft raised shares of Sanofi from a “sell” rating to a “hold” rating in a research note on Thursday, January 30th. StockNews.com downgraded shares of Sanofi from a “buy” rating to a “hold” rating in a research note on Thursday, December 12th. Finally, Sanford C. Bernstein raised shares of Sanofi to a “strong-buy” rating in a research note on Thursday, January 30th. Two analysts have rated the stock with a hold rating, one has given a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, Sanofi currently has a consensus rating of “Buy” and an average target price of $60.00.

Sanofi Stock Performance

NASDAQ SNY opened at $53.50 on Monday. Sanofi has a fifty-two week low of $45.22 and a fifty-two week high of $58.97. The company has a market cap of $135.77 billion, a P/E ratio of 21.49, a P/E/G ratio of 1.26 and a beta of 0.57. The company has a debt-to-equity ratio of 0.15, a quick ratio of 0.74 and a current ratio of 1.46. The business’s 50 day moving average price is $49.44 and its 200-day moving average price is $52.34.

Sanofi (NASDAQ:SNY) last posted its earnings results on Thursday, January 30th. The company reported $0.70 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.70. Sanofi had a net margin of 12.77% and a return on equity of 25.58%.

Institutional Investors Weigh In On Sanofi

Institutional investors have recently modified their holdings of the business. Franklin Resources Inc. boosted its stake in Sanofi by 13.1% during the 3rd quarter. Franklin Resources Inc. now owns 3,407,452 shares of the company’s stock worth $208,106,000 after purchasing an additional 395,744 shares during the last quarter. Natixis Advisors LLC lifted its position in Sanofi by 4.1% during the third quarter. Natixis Advisors LLC now owns 2,874,193 shares of the company’s stock worth $165,640,000 after buying an additional 114,133 shares in the last quarter. Raymond James & Associates boosted its stake in Sanofi by 4.8% during the third quarter. Raymond James & Associates now owns 2,819,348 shares of the company’s stock worth $162,479,000 after buying an additional 129,472 shares during the last quarter. JPMorgan Chase & Co. grew its holdings in shares of Sanofi by 20.9% in the third quarter. JPMorgan Chase & Co. now owns 2,310,809 shares of the company’s stock valued at $133,172,000 after purchasing an additional 399,301 shares during the period. Finally, DAVENPORT & Co LLC boosted its holdings in Sanofi by 40.7% in the 4th quarter. DAVENPORT & Co LLC now owns 2,295,569 shares of the company’s stock valued at $110,715,000 after purchasing an additional 664,455 shares during the last quarter. 14.04% of the stock is currently owned by institutional investors and hedge funds.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.